HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells

被引:39
作者
Ammerpohl, O
Thormeyer, D
Khan, Z
Appelskog, IB
Gojkovic, Z
Almqvist, PM
Ekström, TJ
机构
[1] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Stockholm, Sweden
[2] Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden
[3] ZGene AS, DK-2800 Lyngby, Denmark
[4] AstraZeneca R&D, Sodertalje, Clin Sci, S-15185 Sodertalje, Sweden
关键词
HSV-tk; bystander killing; HDAC inhibitor; 4-phenylbutyrate; ganciclovir; glioma; gap junction;
D O I
10.1016/j.bbrc.2004.09.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant glioma patients have a dismal prognosis with an urgent need of new treatment modalities. Previously developed gene therapies for brain tumors showed promising results in experimental animal models, but failed in clinical trials due to low transfection rates and insufficient expression of the transgene in tumor cells, as well as low bystander killing effects. We have previously shown that the histone deacetylase inhibitor 4-phenylbutyrate (4-PB) enhances gap junction communication between glioma cells in culture. In this study, we demonstrate an activation of recombinant HSV-tk gene expression, and a dramatic enhancement of gap junction-mediated bystander killing effect by administration of the HSV-tk prodrug ganciclovir together with 4-PB. These findings that 4-PB potentiates "suicide gene" expression as well as enhances gap junctional communication and bystander killing of tumor cells justify further testing of this paradigm as an adjunct to suicide gene therapy of malignant gliomas. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 40 条
  • [1] Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells
    Asklund, T
    Appelskog, IB
    Ammerpohl, O
    Ekström, TJ
    Almqvist, PM
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) : 1073 - 1081
  • [2] Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene
    Asklund, T
    Appelskog, IB
    Ammerpohl, O
    Langmoen, IA
    Dilber, MS
    Aints, A
    Ekström, TJ
    Almqvist, PM
    [J]. EXPERIMENTAL CELL RESEARCH, 2003, 284 (02) : 185 - 195
  • [3] New roles for astrocytes:: Gap junction hemichannels have something to communicate
    Bennett, MVL
    Contreras, JE
    Bukauskas, FF
    Sáez, JC
    [J]. TRENDS IN NEUROSCIENCES, 2003, 26 (11) : 610 - 617
  • [4] Connections with connexins: The molecular basis of direct intercellular signaling
    Bruzzone, R
    White, TW
    Paul, DL
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 238 (01): : 1 - 27
  • [5] CHEN JS, 2003, CURR CANCER DRUG TAR, V3, P129
  • [6] COLE SPC, 1986, CANCER CHEMOTH PHARM, V17, P259
  • [7] THE BYSTANDER EFFECT - ASSOCIATION OF U-87 CELL-DEATH WITH GANCICLOVIR-MEDIATED APOPTOSIS OF NEARBY CELLS AND LACK OF EFFECT IN ATHYMIC MICE
    COLOMBO, BM
    BENEDETTI, S
    OTTOLENGHI, S
    MORA, M
    POLLO, B
    POLI, G
    FINOCCHIARO, G
    [J]. HUMAN GENE THERAPY, 1995, 6 (06) : 763 - 772
  • [8] Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents
    De Clercq, E
    Andrei, G
    Snoeck, R
    De Bolle, L
    Naesens, L
    Degrève, B
    Balzarini, J
    Zhang, Y
    Schols, D
    Leyssen, P
    Ying, C
    Neyts, J
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) : 271 - 285
  • [9] Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes
    Denning, C
    Pitts, JD
    [J]. HUMAN GENE THERAPY, 1997, 8 (15) : 1825 - 1835
  • [10] Denny WA, 2003, J BIOMED BIOTECHNOL, P48